Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $101.5000 (2.11%) ($100.1000 - $107.8000) on Mon. Nov. 21, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.39% (three month average) | RSI | 64 | Latest Price | $101.5000(2.11%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX advances 5.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKK(9%) QQQ(9%) SKYY(9%) SMH(9%) IBB(8%) | Factors Impacting HTBX price | HTBX will decline at least -2.195% in a week (0% probabilities). VCSH(-7%) VIXM(-5%) XLU(-2%) XHB(-2%) UUP(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.195% (StdDev 4.39%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $101.94(-0.43%) | 10 Day Moving Average | $99.59(1.92%) | 20 Day Moving Average | $97.09(4.54%) | To recent high | -17.6% | To recent low | 25.5% | Market Cap | $11.167b | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |